Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918320 | 1.00 | CYP2C9 (0.36) | CYP2C9CYP2C19TDP1LMNACA12 | |
| SCHEMBL4908359 | 0.88 | — | — | |
| SCHEMBL10108995 | 0.86 | CYP2C19 (0.50) | CYP2C9CYP2C19TDP1LMNACA12 | |
| SCHEMBL10108794 | 0.84 | CYP2C19 (0.52) | CYP2C9CYP2C19TDP1LMNACA12 | |
| SCHEMBL18677086 | 0.84 | CYP2C9 (0.38) | CYP2C9CYP2C19CA12CA6CA7 | |
| SCHEMBL10108999 | 0.80 | CYP2C19 (0.56) | CYP2C9CYP2C19TDP1LMNACA12 | |
| SCHEMBL23153211 | 0.79 | CYP2C9 (0.38) | CYP2C9CYP2C19TDP1 | |
| SCHEMBL9738325 | 0.77 | TDP1 (0.32) | CYP2C9CYP2C19TDP1 | |
| SCHEMBL861103 | 0.75 | CA12 (0.58) | CYP2C9CYP2C19TDP1LMNACA12 | |
| SCHEMBL861101 | 0.75 | CA12 (0.58) | CYP2C9CYP2C19TDP1LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914254-B1 | Crosslinkers for improving stability of polyurethane foams | EVONIK DEGUSSA GMBH (DE) | 2017-08-23 | — | — | EP | claimed |
| EP-1914254-A1 | Crosslinkers for improving stability of polyurethane foams | Air Products and Chemicals, Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| US-20080090922-A1 | Crosslinkers for improving stability of polyurethane foams | EVONIK OPERATIONS GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| EP-3390483-B1 | ENCAPSULATION | PROCTER & GAMBLE (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3368207-B1 | ENCAPSULATION | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10864167-B2 | Encapsulation | THE PROCTER & GAMBLE COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| US-20180235893-A1 | ENCAPSULATION | THE PROCTER & GAMBLE COMPANY | 2018-08-23 | — | — | US | disclosed |
| US-9937477-B2 | Encapsulation | WATERTITE PRODUCTS, INC. | 2018-04-10 | — | — | US | disclosed |
| EP-1914254-B1 | Crosslinkers for improving stability of polyurethane foams | EVONIK DEGUSSA GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-20170113200-A1 | Encapsulation | Encapsys,LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-8552078-B2 | Non-fugitive tertiary amine catalyst and alkylated polyamine crosslinking additives; aging resistance | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-1914254-A1 | Crosslinkers for improving stability of polyurethane foams | Air Products and Chemicals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090922-A1 | Crosslinkers for improving stability of polyurethane foams | EVONIK OPERATIONS GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235893-A1 | ENCAPSULATION | ACR, ACMSD, SAMM50 | CYP2C9 2054/4885CYP2C19 1591/4885TDP1 810/4885 |
| US-10864167-B2 | Encapsulation | ACR, MPHOSPH6, ACMSD | CYP2C9 2162/4885CYP2C19 1634/4885TDP1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.